JP2022544825A5 - - Google Patents

Info

Publication number
JP2022544825A5
JP2022544825A5 JP2022510857A JP2022510857A JP2022544825A5 JP 2022544825 A5 JP2022544825 A5 JP 2022544825A5 JP 2022510857 A JP2022510857 A JP 2022510857A JP 2022510857 A JP2022510857 A JP 2022510857A JP 2022544825 A5 JP2022544825 A5 JP 2022544825A5
Authority
JP
Japan
Prior art keywords
genetically modified
cells
population
pharmaceutical product
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022510857A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022544825A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/047202 external-priority patent/WO2021035054A1/en
Publication of JP2022544825A publication Critical patent/JP2022544825A/ja
Publication of JP2022544825A5 publication Critical patent/JP2022544825A5/ja
Pending legal-status Critical Current

Links

JP2022510857A 2019-08-20 2020-08-20 細胞免疫療法のためのリンパ球枯渇投与レジメン Pending JP2022544825A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962889338P 2019-08-20 2019-08-20
US62/889,338 2019-08-20
US202063061070P 2020-08-04 2020-08-04
US63/061,070 2020-08-04
PCT/US2020/047202 WO2021035054A1 (en) 2019-08-20 2020-08-20 Lymphodepletion dosing regimens for cellular immunotherapies

Publications (2)

Publication Number Publication Date
JP2022544825A JP2022544825A (ja) 2022-10-21
JP2022544825A5 true JP2022544825A5 (https=) 2023-08-29

Family

ID=72291163

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022510857A Pending JP2022544825A (ja) 2019-08-20 2020-08-20 細胞免疫療法のためのリンパ球枯渇投与レジメン

Country Status (6)

Country Link
US (1) US20220273720A1 (https=)
EP (1) EP4017526A1 (https=)
JP (1) JP2022544825A (https=)
AU (1) AU2020333851A1 (https=)
CA (1) CA3148179A1 (https=)
WO (1) WO2021035054A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY
EP4337228A4 (en) * 2021-05-13 2025-07-30 Nkarta Inc DOSAGE REGIMEN FOR CANCER IMMUNOTHERAPY
JP2024520444A (ja) 2021-05-24 2024-05-24 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を治療するための方法
KR20240023522A (ko) * 2021-05-24 2024-02-22 프로벤션 바이오, 인코포레이티드 감염 후 자가면역성 당뇨병을 치료하는 방법
WO2023091910A1 (en) * 2021-11-16 2023-05-25 Precision Biosciences, Inc. Methods for cancer immunotherapy
WO2023108150A1 (en) * 2021-12-10 2023-06-15 Precision Biosciences, Inc. Methods for cancer immunotherapy
CN121752276A (zh) * 2023-09-08 2026-03-27 菲特治疗公司 用于自身免疫疾病治疗的iPSC衍生的效应细胞

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
DE69534629D1 (de) 1994-01-18 2005-12-29 Scripps Research Inst Derivate von zinkfingerproteinen und methoden
US6140466A (en) 1994-01-18 2000-10-31 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
GB9824544D0 (en) 1998-11-09 1999-01-06 Medical Res Council Screening system
USRE39229E1 (en) 1994-08-20 2006-08-08 Gendaq Limited Binding proteins for recognition of DNA
US5789538A (en) 1995-02-03 1998-08-04 Massachusetts Institute Of Technology Zinc finger proteins with high affinity new DNA binding specificities
US7696338B2 (en) 1995-10-30 2010-04-13 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxin fusion proteins and means for expression thereof
US5925523A (en) 1996-08-23 1999-07-20 President & Fellows Of Harvard College Intraction trap assay, reagents and uses thereof
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
US6015832A (en) 1997-12-31 2000-01-18 The Regents Of The University Of Michigan Methods of inactivating bacteria including bacterial spores
US6559189B2 (en) 1999-04-28 2003-05-06 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
US6506803B1 (en) 1999-04-28 2003-01-14 Regents Of The University Of Michigan Methods of preventing and treating microbial infections
US6635676B2 (en) 1999-04-28 2003-10-21 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
US7767216B2 (en) 1999-04-28 2010-08-03 The Regents Of The University Of Michigan Antimicrobial compositions and methods of use
HK1047109A1 (zh) 1999-10-15 2003-02-07 University Of Massachusetts 作为指定基因干预工具的rna干预轨迹基因
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
US20020061512A1 (en) 2000-02-18 2002-05-23 Kim Jin-Soo Zinc finger domains and methods of identifying same
AU2001263155A1 (en) 2000-05-16 2001-11-26 Massachusetts Institute Of Technology Methods and compositions for interaction trap assays
AU2001275474A1 (en) 2000-06-12 2001-12-24 Akkadix Corporation Materials and methods for the control of nematodes
US6555674B2 (en) 2000-08-09 2003-04-29 Nsgene A/S JeT promoter
GB0108491D0 (en) 2001-04-04 2001-05-23 Gendaq Ltd Engineering zinc fingers
WO2003087341A2 (en) 2002-01-23 2003-10-23 The University Of Utah Research Foundation Targeted chromosomal mutagenesis using zinc finger nucleases
WO2003080809A2 (en) 2002-03-21 2003-10-02 Sangamo Biosciences, Inc. Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
US7074596B2 (en) 2002-03-25 2006-07-11 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthesis and use of anti-reverse mRNA cap analogues
EP2806025B1 (en) 2002-09-05 2019-04-03 California Institute of Technology Use of zinc finger nucleases to stimulate gene targeting
US20070134796A1 (en) 2005-07-26 2007-06-14 Sangamo Biosciences, Inc. Targeted integration and expression of exogenous nucleic acid sequences
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
CA2569509C (en) 2004-06-03 2014-08-12 Novimmune S.A. Anti-cd3 antibodies and methods of use thereof
PL2578685T3 (pl) 2005-08-23 2020-01-31 The Trustees Of The University Of Pennsylvania Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania
ES2582091T3 (es) 2005-10-18 2016-09-09 Precision Biosciences Meganucleasas diseñadas racionalmente con especificidad de secuencia y afinidad de unión a ADN alteradas
EP2215223B1 (en) 2007-10-31 2013-05-01 Precision Biosciences, Inc. Rationally-designed single-chain meganucleases with non-palindromic recognition sequences
EP2206723A1 (en) 2009-01-12 2010-07-14 Bonas, Ulla Modular DNA-binding domains
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
TR201904484T4 (tr) 2009-11-03 2019-05-21 Hope City Transdüse T hücre seçimine yönelik kesik epiderimal büyüme faktörü reseptörü (EGFRt).
US8956828B2 (en) 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
WO2011072246A2 (en) 2009-12-10 2011-06-16 Regents Of The University Of Minnesota Tal effector-mediated dna modification
CA3111953C (en) 2011-04-05 2023-10-24 Cellectis Method for the generation of compact tale-nucleases and uses thereof
GB201206559D0 (en) 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
EP3498305A1 (en) 2012-04-20 2019-06-19 Angimmune Llc Immunomodulation by anti-cd3 immunotoxins to treat cancers not uniformly bearing surface cd3
BR112014029417B1 (pt) * 2012-05-25 2023-03-07 Cellectis Método ex vivo para a preparação de células t para imunoterapia
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
US9937207B2 (en) 2013-03-21 2018-04-10 Sangamo Therapeutics, Inc. Targeted disruption of T cell receptor genes using talens
ES2716867T3 (es) 2013-05-31 2019-06-17 Cellectis Sa Endonucleasa de asentamiento LAGLIDADG que escinde el gen de receptor de células T alfa y usos de la misma
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
JP6816133B2 (ja) 2015-10-05 2021-01-20 プレシジョン バイオサイエンシズ，インク． 改変ヒトｔ細胞受容体アルファ定常領域遺伝子を含む遺伝子改変細胞
EP3359660B1 (en) 2015-10-05 2019-12-04 Precision Biosciences, Inc. Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene
CN116617387A (zh) 2016-08-29 2023-08-22 迪赞纳生命科学公开有限公司 抗cd3抗体制剂
DK3523326T3 (da) 2016-10-04 2020-08-03 Prec Biosciences Inc Samstimulerende domæner til anvendelse i genetisk modificerede celler
EP4269560A3 (en) 2017-10-03 2024-01-17 Precision Biosciences, Inc. Modified epidermal growth factor receptor peptides for use in genetically-modified cells
WO2021113543A1 (en) * 2019-12-06 2021-06-10 Precision Biosciences, Inc. Methods for cancer immunotherapy, using lymphodepletion regimens and cd19, cd20 or bcma allogeneic car t cells

Similar Documents

Publication Publication Date Title
JP2022544825A5 (https=)
Tapia-Galisteo et al. Bi-and trispecific immune cell engagers for immunotherapy of hematological malignancies
Goebeler et al. T cell-engaging therapies—BiTEs and beyond
Duell et al. Bispecific antibodies in the treatment of hematologic malignancies
Stein et al. Blinatumomab for acute lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell transplantation
Aldoss et al. Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors
Zekri et al. An IgG‐based bispecific antibody for improved dual targeting in PSMA‐positive cancer
US20260102510A1 (en) Conditioning for in vivo immune cell engineering
JP7573441B2 (ja) ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法
Shabaneh et al. Systemically administered low-affinity HER2 CAR T cells mediate antitumor efficacy without toxicity
JP2022159548A5 (https=)
US20240041930A1 (en) Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells
EP2604278A1 (en) Anti-KIR antibodies, formulations, and uses thereof
Zhang et al. Activating Fc receptors are required for antitumor efficacy of the antibodies directed toward CD25 in a murine model of adult T-cell leukemia
JP2015163068A5 (https=)
US20230270857A1 (en) Compositions including ex vivo armed t cells with multi-specific antibodies and uses thereof
Wang et al. Nanobody-armed T cells endow CAR-T cells with cytotoxicity against lymphoma cells
JP2022513689A5 (https=)
Guo et al. Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment
JP2020502147A (ja) 制御性ｂ１０細胞を枯渇させる抗体および方法並びに免疫チェックポイント阻害剤との併用における使用
JP2024518776A5 (https=)
JP2023537002A5 (https=)
Lyons et al. Bispecific T-cell engagers in childhood B-acute lymphoblastic leukemia
Castaneda-Puglianini et al. Bispecific antibodies for non-Hodgkin’s lymphomas and multiple myeloma
JP2023540255A5 (https=)